Related Experiment Video
Updated: Aug 10, 2026
Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
Fibrosis regression induced by intravenous gammaglobulin treatment
1Research Unit of Autoimmune Diseases and Department of Medicine B, Sheba Medical Centre, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Hashomer, Israel.
Objectives:
To review case histories of patients in whom fibrosis played a significant role in the pathogenesis of their disease, and to determine whether intravenous gammaglobulin (IVIg) contributed to the regression of their fibrotic condition.
Methods:
Eight patients with excess fibrotic reaction in the course of diverse diseases were analysed; a tendency that reverted with different IVIg treatment options. Myelofibrosis was predominant in three patients (a patient with a myeloproliferative syndrome, one with systemic lupus erythematosus, and one with Sjögren's syndrome). Three patients had scleroderma as their main feature, one patient had hepatitis C cirrhosis, and one had idiopathic thrombocytopenic purpura.
Results:
Fibrotic excess was reduced in all the patients by IVIg treatment. In five patients the disease as a whole benefited from the infusion of immunoglobulins.
Conclusion:
IVIg may enhance resorption of fibrosis and promote healing in patients with fibrotic associated disorders.
